Current clinical standards for immunotherapy prescription either do not include any stratification of the patients with a specific tumor type (e.g., melanoma) or suggest patient selection based on PD-L1 expression by tumor cells (e.g., lung cancer) [40]. The gene discussed is CD274; the disease is melanoma.